Two cis-diamminedichloroplatinum(II) (cisplatin)-inducible proteins [b130 ( 130 kDa) and b,5 (-95 kDa)] in HeLa cells that recognize both the cisplatin-modified and u.v.-modified DNA were identified in this study. These damage-recognition proteins were overexpressed in cisplatin-resistant HeLa cells. The results suggest that the damage-recognition proteins are regulated in the cells in response to DNA damage, and they may be important for DNA repair and probably the emergence of cisplatin resistance.
INTRODUCTION
The development of drug resistance in cancer patients causes a major hindrance to cancer treatment [1] [2] [3] [4] . Cellular resistance to cis-diamminedichloroplatinum(II) (cisplatin), a widely used chemotherapeutic agent, is not an exception, although the mechanism is not clear. To accomplish further understanding of cisplatin resistance, appreciation has been found through studies of cultured cells. The substantial lines of indirect evidence that have accumulated have suggested that the cisplatin-resistant phenotype is usually associated with enhanced DNA repair, although other mechanisms, such as membrane-associated drug efflux, may also be involved [4] .
Effective DNA repair in cells depends upon an efficient coupling of the repair enzymes to the target domain of the damaged chromosomal DNA [5] . It is reasonable to say that a similar repair environment can be partly mimicked in vitro by using plasmid DNA and isolated cellular proteins. Such a system has recently been established (e.g. [6] [7] [8] [9] ). To gain a further understanding of cisplatin resistance in human cells, assays involving South-Western blotting [10, 11] and gel-mobility shift [12, 13] were used. In the present study, we find that cellular factors which recognize cisplatin-modified DNA as well as u.v.-modified DNA were inducible by cisplatin. A cisplatin-resistant cell line, which was also cross-resistant to u.v. {14], showed an overexpression of these damage-recognition proteins (DRPs [14] . Resistant [16] . The f103 DNA (see below) was treated in the dark with cisplatin in 3 mM-NaCl/I mM-sodium phosphate (pH 7.4), at 37°C for 18-24 h [17] . The DNA concentration was 100 /sg/ml (2 x 10-4 M-nucleotide phosphate). After treatment, the concentration of NaCl was increased to 0.1 M, and the modified DNA was precipitated by standard methods [18] [19] . Cells were lysed with lysis buffer I (0.50% Triton X-100/10 mM-Hepes (pH 8.0)/0.5 M-sucrose/ 50 mM-NaCI/10 mM-MgCl2/1 mM-dithiothreitol). The nuclei were then collected by centrifugation and lysed with lysis buffer II (lysis buffer I plus 0.5M-NaCl and 10mM-spermidine). High-molecular-mass DNA was removed from the lysate by centrifugation, and the supernatant was collected and dialysed against dialysis buffer [50% (v/v) glycerol/10 mmHepes (pH 8.0)/50 mM-NaCl/ 10 mM-MgCl2/1 mM-dithiothreitol]. Quantification of the protein concentration was performed by the Bradford method [20] .
Nuclear proteins were separated in an SDS/4-10 %-gradientpolyacrylamide gel without prior boiling of the samples. The separated proteins were electrophoretically transferred from the gel to poly(vinylidene difluoride) ('PVDF') filters (Millipore). The filters were soaked in a blocking buffer [10 Vol. 277 C. C.-K. Chao and others Hepes (pH 8.0)/50 mM-NaCl/ 10 mM-MgC12/ 1 mM-dithiothreitol/0.25 % non-fat milk] containing 5 x 107 c.p.m. of DNA probe. The filters were then washed twice for 1 h each with washing buffer (binding buffer without DNA probe and with 150 mM-NaCl instead of 50 mM). The semi-dried filters were then subjected to Kodak XAR-5 X-ray films for autoradiography. The relative expression of DNA-binding proteins was determined by scanning densitometry of the X-ray film.
DNA probes and gel-mobility-shift assay
The 130 bp SphI-Bgll fragment from plasmid pSVT [21] was ligated to SphI-SmaI-opened vector pBS(+) (Stratagene, La Jolla, CA, U.S.A.) at the SphI site. The BglI site was blunted with Klenow DNA polymerase (New England Biolabs, Beverly, MA, U.S.A.) and ligated to the SmaI site. The f130 fragment containing the 17 bp dA/dT-rich region, which is a potential target for u.v. modification, was then generated with HindIII and EcoRI (hereinafter called 'fl30'). The DNA fragment f103 [6] was the 103 bp StuI-AvaII fragment from recombinant plasmid pCD-a-globin [22] , filled, attached to EcoRI and XbaI linkers respectively, and cloned into pBS(+). The HindIII-EcoRI-cutout fragment (hereinafter called 'f1O3') contains a 14 bp string of dG-dC-rich region which is a potential target for cisplatin modification. Hindlll-EcoRI-generated f103 or f130 fragments were 32P-labelled (-3 x 104 c.p.m./ng of DNA) with Klenow DNA polymerase and spin-column-purified by standard methods [18] .
The gel-mobility-shift assay was performed as described [12, 13] . Briefly, 104 c.p.m. of u.v.-modified f130 (1000 J/m2) or cisplatin-modified f103 (rf = 0.08), unless otherwise indicated, was incubated with nuclear extracts at 30°C for 30 min. The reaction mixtures were then separated by 4%-PAGE in lowionic-strength buffer at 25°C and 15 mA constant current. The resolved gels were directly exposed to a Kodak XAR-5 X-ray film without further processing. Densitometry was used to quantify the intensity of the binding bands on the autoradiogram.
RESULTS
To identify inducible cellular factors that interact with the damaged forms of DNA, exponentially growing cells were treated with cisplatin. Nuclear proteins were prepared and processed for South-Western blotting, then probed with 5 x 107 c.p.m. each of the unmodified fl03 and fl30 (Fig. la) 1 and 4) . It became even more dramatic after induction (cf. lanes 2 and 5). A 160 kDa factor (b60) that was overexpressed in resistant cells was also identified. However, binding of b60 was less consistent and it was able to interact with the unmodified DNA probe (also see Fig. 2 ). Therefore, it should not be considered as a damage-inducible protein. In addition, a -25 kDa cellular protein (b25) that interacts with damaged as well as undamaged forms of the DNA was monitored in the present study. In contrast with the inducible b130 and b95, b25 was very sensitive to cisplatin; it was immediately inhibited in response to the treatment (compare lanes 1 and 2) (Fig. 2b) or cisplatin-modified f103 (Fig. 2c) . As shown, b95 from either induced (+) or noninduced (-) cells also binds to u.v.-modified DNA, although less intensely than to cisplatin-modified DNA. b130 also interacts with u.v.-modified DNA, but binds preferentially to the cisplatinmodified DNA. It should be noted that the amount of probes used for the control experiment (Fig. 2a) was doubled. Similar results were obtained using parental-cell nuclear extracts (results not shown). Therefore the inducible binding of b95 and b130 to u.v.-modified DNA should be significant. An alternative to South-Western blotting for the detection of DNA-protein interaction is using gel-mobility shift. Fig. 3 shows the typical results. A 2 ,ug portion of crude nuclear extracts from resistant (R) or parental (P) cells were incubated with u.v.-modified f130 (Fig. 3a) or cisplatin-modified f103 (Fig. 3b) probe. The level of both binding proteins (indicated with arrowheads) was dependent upon the severity of the DNA lesion (see the legend to Fig. 3 for details) . It is apparent that the DRPs were overexpressed in resistant cells.
To demonstrate further the independence of the identified cisplatin-modified and u.v.-modified DNA-binding proteins in gel-shift studies, competition assays were carried out. With increasing damage to the u.v.-modified DNA probe (Fig. 4,  panel a; lanes 2-5) , the u.v.-modified DNA-binding activities from parental extracts (indicated by Bi and B2) were increasingly enhanced. When a fixed amount of cisplatin-modified DNA probe was included in the reaction mixture, the increased u.v.-modified DNA binding did not significantly affect the cisplatin-modified-DNA binding activities (indicated by bl and b2 in Fig. 3b) . Extracts from resistant cells gave similar binding patterns (results not shown). The results indicate the different mobilities of u.v.-modified-DNA and cisplatin-modified-DNA binding complexes.
DISCUSSION
We have applied South-Western blotting to study DNAprotein binding and identified two damage-inducible cellular proteins that bind to damaged DNA. These DRPs were overexpressed in cisplatin-resistant cells. Studies using gel-mobility shifts also showed enhanced DRPs in resistant cells. Competition analysis suggests that cisplatin-modified-DNA-binding protein is independent of u.v. In the present study we have also identified b25, a binding protein suppressible by cisplatin and absent in resistant cells. This factor is also inhibited by u.v. (results not shown). It is reasonable to believe that cisplatin can elicit the expression of DRPs, presumably because these inducible molecules are required for DNA repair, and especially so because these cisplatin-inducible DRPs are overexpressed in resistant cells. In addition, resistant cells also showed cross-resistance to u.v. [14] . Therefore it is not surprising that u.v.-modified-DNA-binding proteins were also overexpressed in resistant cells [9, 23] . However, it is difficult to imagine why b25 is not inducible and is absent from resistant cells. One possibility is that b25 plays a role in cisplatin resistance through negative regulation. f
